Late-Breaking Oral Presentation at SHSA 2026

We are delighted to announce that ELN28 has been selected for a late-breaking oral presentation at SHSA 2026 in Arizona.
This represents a major milestone for ELN28 and Elasmogen Ltd, and marks the first Elasmogen asset selection for a late-breaking session at an international HS clinical and scientific conference.
Prof John Frew, an internationally recognised clinician and researcher in Hidradenitis Suppurativa, will present findings from our HS biopsy ex vivo study, highlighting inflammatory suppression and stromal remodelling following treatment with ELN28.
Obinna C Ubah from the Elasmogen team will also be attending and would be delighted to connect.

#SHSA2026 #Hidradenitis Suppurativa #ELN28 #Elasmogen